Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review)

Tibor Görögh1, Ulf Henning Beier

  • 1Division of Experimental Oncology, Department of Otorhinolaryngology Head and Neck Surgery, University of Schleswig Holstein, Campus Kiel, D-24105 Kiel, Germany. gorogh@hno.uni-kiel.de

Insights

Survival for head and neck squamous cell carcinoma (HNSCC) is poor due to limited targeted therapies. This review covers HNSCC molecular understanding and promising new treatments for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head and neck squamous cell carcinoma (HNSCC) survival rates remain low despite advances in prevention, detection, and treatment.
  • Current therapeutic strategies for HNSCC are limited, particularly for advanced stages, due to a lack of molecularly targeted options beyond general mitosis inhibition.

Purpose of the Study:

  • To review the current understanding of the molecular mechanisms underlying head and neck squamous cell carcinoma (HNSCC) carcinogenesis.
  • To highlight promising novel therapeutic agents and strategies for HNSCC.

Main Methods:

  • Literature review of scientific articles and clinical studies.
  • Analysis of data on HNSCC carcinogenesis and molecular targets.
  • Evaluation of emerging therapeutic approaches, including targeted therapies.

Main Results:

  • Significant progress has been made in understanding HNSCC molecular pathways over the past 30 years.
  • Epidermal growth factor receptor (EGFR) blockers represent one class of novel therapeutic agents.
  • Several other promising molecular targets and therapeutic strategies are emerging.

Conclusions:

  • A deeper understanding of HNSCC molecular carcinogenesis is crucial for developing effective treatments.
  • Targeted therapies offer significant potential to improve outcomes for HNSCC patients.
  • Continued research into molecular mechanisms and targeted agents is essential for advancing HNSCC care.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...